Latest News - Psoriasis

Thursday, July 27, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Atopic Derm, Atopic Dermatitis , Eczema, Psoriasis, Valeant NJ

Valeant’s Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AAD

It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch …

Read the full story

Wednesday, May 24, 2017 | PracticalDermatology.com, Research and Publications, 23andMe , Psoriasis

Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clues

A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how -- and why -- psoriasis develops. University of Michigan researchers, wor…

Read the full story

Tuesday, May 23, 2017 | PracticalDermatology.com, PracticalDermatology.com, Research and Publications, Psoriasis

Tweaking TWEAK May Cool Inflammation in Pso and AD

New research pinpoints a common driver of skin inflammation in both psoriasis and atopic dermatitis. The findings, published in the May 22, 2017 issue of Nature Communications, showed that TWE…

Read the full story

Monday, March 06, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Novartis, Psoriasis

Sandoz Proposed Biosimilar Shows Equivalent Efficacy to Humira

Sandoz’s proposed biosimilar adalimumab (GP2017) shows equivalent efficacy to reference medicine, according to data presented at the American Academy of Dermatology (AAD) in Orlando, Florida. …

Read the full story

Wednesday, November 16, 2016 | Research and Publications, Novan, Psoriasis

Novan: SB414 Inhibited IL-17 in Psoriasis Mouse Model

Novan, Inc. has announced preclinical data showing that its nitric oxide-releasing product candidate SB414 significantly (p<0.05) reduced composite psoriasis scores, which consist of eryt…

Read the full story

Friday, September 23, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Amgen, Psoriasis

FDA Approves Humira Biosimilar

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following ind…

Read the full story

Wednesday, July 27, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Psoriasis

Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europe

Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currentl…

Read the full story

Tuesday, July 19, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Psoriasis, Valeant NJ

FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasis

A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committe…

Read the full story

Wednesday, June 01, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Promius, Psoriasis

Sernivo Spray Hits Pharmacy Shelves

Sernivo™ Spray for psoriasis is officially available. Dr. Reddy’s Laboratories’ US subsidiary, Promius Pharma, LLC, U.S. Sernivo™ Spray (betamethasone dipropionate) 0.05% wa…

Read the full story

Wednesday, April 13, 2016 | Business of Medicine, PracticalDermatology.com, AbbVie, Amgen, Johnson & Johnson, Psoriasis

Psoriasis Market Poised for Growth Spurt by 2024

The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a new report from GlobalData. The market will rise from $6.6 billion in 2014 to over …

Read the full story